May 10, 2019
Ocular Therapeutix posts net loss of $17.1 million in the first quarter of 2019
Ocular Therapeutix posts net loss of $17.1 million in the first quarter of 2019
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
May 10, 2019
Teva launches generic Tarceva (erlotinib) tablets in the United States
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has launched a generic version of Tarceva®1(erlotinib) tablets, 100 and 150 mg, in the U.S.
May 9, 2019
Global Opioids Market – Rising Focus on Abuse-deterrent Formulation (ADF) by Generic Manufacturers
Due to an increase in the incidence of medical ailments, the marketstudied is expected to grow over the forecast period.
May 9, 2019
LabShares Newton Selects Savran Technologies as Winner of First Launch@LabShares Competition Valued at $50K
Second Launch@Shares Competition Announced in Collaboration withMTTC/MALSI Conference and MassBio’s MassCONNECT Program
May 9, 2019
The $3.12Bn Global Food Enzymes Market by Source, Type, Form, Application and Geography – Forecast to 2024
The global food enzymes market is expected to grow at a CAGR of 7.5%from 2019 to reach $3,125.1 million by 2024 from $2,176.9 million in2019.
May 9, 2019
Recipharm launches Recipharm Inhalation SolutionsTM as its end-to-end offering for inhalation products
Recipharm, the contract development and manufacturing organisation (CDMO), has launched its end-to-end inhalation offering to provide customers with a fully integrated service from early stage development through to commercial manufacturing.
May 9, 2019
Vivimed Life Sciences recalls Losartan Potassium three doses tablets, USP due traces of N-Nitroso-N-methyl-4-aminobutyric acid
Vivimed Life Sciences recalls Losartan Potassium three doses tablets, USP due traces of N-Nitroso-N-methyl-4-aminobutyric acid
May 9, 2019
Nuvera launches Standard for Measuring HCP satisfaction with pharma support programs
Nuvera launches ThePURE Report, the first independent, standardized, annual assessmentof healthcare provider (HCP) satisfaction with pharmaceutical companies’patient support services, including their industry rankings againstcompetition.
May 9, 2019
Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 22, 2019
Transgene Combined General Meeting (ordinary and extraordinary sessions) ofTransgene’s shareholders will be held on May 22, 2019,
May 9, 2019
Dupixent licensed in the EU for severe asthma with type 2 inflammation
The European Commission (EC) has licensed Dupixent (dupilumab), developed by Regeneron and Sanofi, for older than 12 patients as an add-on maintenance treatment for severe asthma with type 2 inflammation.